IL17A and neoplasm: We found that anti-IL-17A Ab injection inhibits PDL1 expression in tumor cells, macrophages, and MDSCs, decreased the number of Treg cells in TILs, and increased the number of IFN-γ-producing CD4+ and CD8+ T cells in TILs in ER-negative tumor-bearing mice.